SOURCE: IntelliCell BioSciences, Inc.

IntelliCell BioSciences, Inc.

October 06, 2015 08:00 ET

IntelliCell BioSciences, Inc. Launches Sales Program for Its FDA Inspected Cellular Therapy Lab Suite

NEW YORK, NY--(Marketwired - Oct 6, 2015) - IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company") (OTCQB: SVFC), a regenerative medicine company pioneering a new proprietary medical process that results in acquiring Stromal Vascular Fraction Cells (SVFC), announced today that it has initiated an extensive sales and marketing program to offer its U.S. Food and Drug Administration (FDA) Inspected and Registered Cellular Lab Suite to Orthopedic and Pain Management facilities across the country. Over the last several months, IntelliCell has developed and trained an experienced and professional network of Independent Sales Representatives in New Jersey, Pennsylvania, Texas, Mississippi, Louisiana, Wisconsin and Minnesota. The Company anticipates enlisting additional sales representatives in several key markets within the next few months.

Dr. Steven Victor, CEO of IntelliCell BioSciences, said, "I look forward to working with the independent sales representatives to deliver our cutting edge technology lab suites to orthopedic and pain doctors across the country."

About IntelliCell BioSciences:
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous Stromal Vascular Fraction Cells (SVFCs) derived from the blood vessels in the adult adipose tissue. IntelliCell BioSciences has developed its own patented technology and protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. This isolation of the cells process is performed in IntelliCell's FDA Registered and Inspected, cGTP cellular lab. IntelliCell will also be seeking to develop technology-licensing agreements with technology developers, universities, and international business entities

About IntelliCell BioSciences Cellular Lab Suite:
IntelliCell has an FDA registered and Inspected Cellular Therapy Lab Suite which offers our Patented Intellectual Property, best in-class equipment, technical expertise and training, quality assurance and FDA registration and support.

Forward-Looking Statements
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "will reach," "will change," "will soon," "should," "could," "would," "may," "can" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

Contact Information

  • CONTACTS:

    Public Relations
    Sean Leous
    Managing Director
    Phone: 1 646 863 8998